Occidental: Look To Buy Alongside Buffett (NYSE:OXY)
Occidental: Look To Buy Alongside Buffett
Source link
Occidental: Look To Buy Alongside Buffett
Source link
CuraTeQ Biologics, the wholly owned step-down subsidiary of Aurobindo Pharma Ltd, on 2 July announced that it has obtained marketing authorisation from the European Commission for its trastuzumab biosimilar, Dazublys. This approval follows the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issuing a positive opinion in April 2025, recommending Dazublys…
Sound bite for Twitter is: Dividend Growth Utility. Results of stock price testing is that the stock price is probably expensive. Debt Ratios are showing that this stock as a lot of debt. The Dividend Payout Ratios (DPR) are mostly good. The current dividend yield is moderate with dividend growth low. See my spreadsheet on…
A proven strategy for generating outsized gains and delivering market-beating returns is to invest in quality growth stocks. You need to identify a portfolio of companies positioned to grow revenue and earnings steadily, which should translate to an appreciation in share prices over time. In this article, I have identified three growth stocks you can…
UNH’s stock collapse is a rare blue-chip event, driven by temporary cost spikes and cyclical headwinds, not a broken business model. Insider and smart money buying—including Berskshire Hathaway’s $1.6B stake—signals deep value and a contrarian opportunity at current depressed valuations. Optum’s vertical integration and earnings power create a moat; at current prices, I believe the…
by Calculated Risk on 4/30/2025 10:00:00 AM From the NAR: Pending Home Sales Jumped 6.1% in March Pending home sales increased 6.1% in March – the greatest month-to-month increase since December 2023 (+7.0%) – according to the National Association of REALTORS®. The Northeast experienced month-over-month losses in transactions, while the Midwest, South and West saw…
Greatmark Investment Partners Inc. grew its position in shares of Elevance Health, Inc. (NYSE:ELV – Free Report) by 9.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 26,082 shares of the company’s stock after purchasin Source link